Current evidence and therapeutic strategies for multiple sclerosis

Seminars in Neurology

Volumn 28, Issue 1, 2008, Pages 56-68

  Wingerchuk, Dean M ^a  

^a MAYO CLINIC   (United States)

Author keywords

interferon; Drug therapy; Glatiramer acetate; Immunosuppression; Mitoxantrone; Multiple sclerosis; Natalizumab

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NEUTRALIZING ANTIBODY; PLACEBO; PREDNISONE; RAZOXANE; RITUXIMAB; TERIFLUNOMIDE;

ANAPHYLAXIS; ARTHRALGIA; BRAIN ATROPHY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; HEADACHE; HUMAN; HYPERSENSITIVITY; INFLUENZA; INJECTION SITE REACTION; LOADING DRUG DOSE; LOW DRUG DOSE; MEDICAL PRACTICE; META ANALYSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; EVIDENCE-BASED MEDICINE; HUMANS; INTERFERONS; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 39449138202     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1019128     Document Type: Review

References (88)

1. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-288
2. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol 2005;4:341-348
3. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127
4. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria..". Ann Neurol 2005;58:840-846
5. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164
6. O'Riordan JI, Thompson AJ, Kingsley DPE, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121:495-503
7. Sailer M, O'Riordan JI, Thompson AJ, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999;52:599-606
8. CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002;59:998-1005
9. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904
10. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582
11. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489-1496
12. Kappos L, Polman C, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249
13. CHAMPIONS Study Group. Interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-684
14. Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004;61:1515-1520
15. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
16. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of MS: Final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
17. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294
18. PRISMS. (Prevention of Relapses and Disability by Interferon -1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
19. PRISMS Study Group, and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-1636
20. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178
21. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003;361:545-552
22. Freedman M, King J, Oger J, et al. Interferons in relapsing remitting multiple sclerosis. Lancet 2003;361:1822-1823 Letter
23. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460
24. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002;59:1496-1506
25. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002;59:1507-1517
26. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-953
27. Noseworthy JH. How much can we learn from long-term extension trials in multiple sclerosis? Neurology 2006;67:930-931
28. Sorensen PS, Koch-Henrisken N, Ravnborg M, et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Mult Scler 2006;12:253-264
29. Ebers G, Traboulsee A, Li D, et al. Final results from the interferon beta-1b 16-year long-term follow-up study. 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Madrid, Spain: September 2006:P666
30. Martinelli Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003;9:349-355
31. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, United Kingdom: John Wiley and Sons Ltd; 2004
32. Cohen J, Rovaris M, Goodman A, et al. Randomised, double-blind, parallel-group, dose-comparison study of glatiramer acetate in relapsing-remitting multiple sclerosis. 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Madrid, Spain: September 2006
33. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-320
34. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005;64:1336-1342
35. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23
36. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353(4):362-368
37. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353(4):369-374
38. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353(4):375-381
39. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med 2005;353(4):414-416
40. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
41. Rudick RA, Stuart WH, Calabresi PA, et al. A randomized, placebo-controlled trial of natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923
42. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-933
43. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747
44. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006;59:748-754
45. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6:431-441
46. Hartung H-P, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, muticentre trial. Lancet 2002;360:2018-2025
47. Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Neurology 2003;61:1332-1338
48. Novantrone [package insert]. Rockland, MA: Serono Inc; 2005
49. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909-913
50. Avasarala JR, Cross AH, Clifford DB, Singer BA, Siegel BA, Abbey EE. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003;9(1):59-62
51. Edan G, Brochet B, Clanet M, et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4 year mean follow-up study. Neurology 2004;62(suppl 5):A493
52. Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002;59:954-955
53. Bernitsas E, Wei W, Mikol DD. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol 2006;59:206-209
54. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497
55. Cohen JA, Cutter GR, Fischer J, Set al, for the IMPACT Investigators. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-687
56. Secondary Progressive Efficacy Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology 2001;56:1496-1504
57. Li DK, Zhao GJ, Paty DW, University of British Columbia MS/MRI Analysis Research Group, and the SPECTRIMS Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS. MRI results. Neurology 2001;56:1505-1518
58. Panitch H, Miller A, Paty D, Weinshenker B, for the North American Study Group on Interferon beta-1b in Secondary. Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-1795
59. Hommes OR, Sorenson PS, Fazekas F, et al. Intravenous immune globulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004;364:1149-1156
60. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004;63:1779-1787
61. Cohen JA, Antel JP. Does interferon beta help in secondary progressive MS? Neurology 2004;63:1768-1769
62. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24
63. Freedman MS, Patry DG, Grand'Maison F, Myles ML, Paty DW, Selchen DH. Canadian MS Working Group. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004;31:157-168
64. Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548-555
65. Rio J, Nos V, Tintore M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-352
66. Giovannoni G, Munschauer FE III, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:465-469
67. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralizing antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148-153
68. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191
69. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 2003;60:634-639
70. Pachner A. Anti-IFNβ antibodies in IFNβ-treated MS patients: summary. Neurology 2003;61(suppl 5):S1-S5
71. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-39
72. Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006;67:1681-1683
73. Francis GS, Rice GPA, Alsop JC, et al. Interferon β-1a in MS. Results following development of neutralizing antibodies in PRISMS. Neurology 2005;65:48-55
74. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon β-1a: a 4-year controlled study. Neurology 2005;65:40-47
75. Giovannoni G, Goodman A. Neutralizing anti-IFN-β antibodies: how much more evidence do we need to use them in practice? Neurology 2005;65:6-8
76. Sorensen PS, Deisenhammer F, Duda P, et al, EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-827
77. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta - assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68:977-984
78. Petersen B, Bendtzen K, Koch-Henriksen N, et al. Persistence of neutralizing antibodies after discontinuation of IFNB therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006;12:247-252
79. Tullman MJ, Lublin FJ. Combination therapy in multiple sclerosis. Curr Neurol Neurosci Rep 2005;5:245-248
80. Pulicken M, Bash CN, Costello K, et al. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis. Mult Scler 2005;11:169-174
81. Jeffery DR, Chepuri N, Durden N, Burdette J. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 2005;11:296-301
82. Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 2005;11:573-582
83. Gladstone DE, Zamkoff KW, Krupp L, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 2006;63:1388-1393
84. Ramtahal J, Jacob A, Das K, Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 2006;253:1160-1164
85. Cree B. Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 2006;12:171-178
86. U.S. Food and Drug Administration. Life-threatening brain infection in patients with systemic lupus erythematosus after rituxan (Rituximab) treatment. Available at: http://www.fda.gov/cder/drug/advisory/rituximab.htm. Accessed May 10, 2007
87. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140
88. O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900